Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

In diabetes care, the MiniMed 780G insulin pump system uses AI algorithms to predict and adjust insulin delivery based on ...

Shares of Transmedics (NASDAQ: TMDX) fell 28.1% in December, according to data from S&P Global Market Intelligence. The stock was already down significantly from its highs heading into the month ...

Per management, TransMedics has a long history and broad experience in the development of warm machine perfusion for organ preservation. During the life of its OCS technology platform, the company ...

TransMedics is transforming organ transplants with advanced technology and integrated logistics. Strong market demand and expanding adoption support long-term growth potential despite the recent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransMedics Group appoints new CFO, Gerardo Hernandez, and adjusts financial outlook for 2024. Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive ...

TransMedics Group, Inc. (NASDAQ:TMDX), a leading player in the organ transplant technology sector with a market capitalization of $2.55 billion, has been making waves in the medical device industry ...

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

TransMedics Group, Inc. TMDX investors are encountering some short-term losses from the stock of late. Shares of the Andover, MA-based commercial-stage medical technology company providing organ ...